[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2012128520A3 - 위식도 역류질환 치료용 액상 타입 조성물 - Google Patents

위식도 역류질환 치료용 액상 타입 조성물 Download PDF

Info

Publication number
WO2012128520A3
WO2012128520A3 PCT/KR2012/001949 KR2012001949W WO2012128520A3 WO 2012128520 A3 WO2012128520 A3 WO 2012128520A3 KR 2012001949 W KR2012001949 W KR 2012001949W WO 2012128520 A3 WO2012128520 A3 WO 2012128520A3
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
reflux disease
gastroesophageal reflux
type composition
treating gastroesophageal
Prior art date
Application number
PCT/KR2012/001949
Other languages
English (en)
French (fr)
Other versions
WO2012128520A2 (ko
Inventor
김정훈
진성규
강경훈
김보견
이혜주
Original Assignee
동아제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아제약 주식회사 filed Critical 동아제약 주식회사
Publication of WO2012128520A2 publication Critical patent/WO2012128520A2/ko
Publication of WO2012128520A3 publication Critical patent/WO2012128520A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 신규한 위식도 역류질환 치료용 조성물에 관한 것이다. 본 발명에 따른 경구용 액상 조성물은, 저점도를 가지므로 환자의 복약편의성이 우수하고, 제조과정이 간단하며, 멸균조작이 용이한 장점을 가지며, 구조적으로 우수한 강도의 부유겔을 형성하여 위식도 역류질환 치료효과를 가진다.
PCT/KR2012/001949 2011-03-23 2012-03-19 위식도 역류질환 치료용 액상 타입 조성물 WO2012128520A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110025860A KR20120108218A (ko) 2011-03-23 2011-03-23 위식도 역류질환 치료용 액상 타입 조성물
KR10-2011-0025860 2011-03-23

Publications (2)

Publication Number Publication Date
WO2012128520A2 WO2012128520A2 (ko) 2012-09-27
WO2012128520A3 true WO2012128520A3 (ko) 2012-11-15

Family

ID=46879876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001949 WO2012128520A2 (ko) 2011-03-23 2012-03-19 위식도 역류질환 치료용 액상 타입 조성물

Country Status (2)

Country Link
KR (1) KR20120108218A (ko)
WO (1) WO2012128520A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016048059A1 (ko) * 2014-09-24 2016-03-31 주식회사 태준제약 알긴산 또는 알긴산 염 및 감초 추출물을 포함하는 위장관 질환 치료용 조성물
KR102309593B1 (ko) * 2019-06-26 2021-10-07 재단법인 강릉과학산업진흥원 알긴산 나트륨을 주성분으로 함유한 위건강용 기능성 음료 조성물 및 이의 제조 방법
WO2024030936A1 (en) 2022-08-02 2024-02-08 Nutrition & Biosciences Usa 1, Llc Modified-release alginate-based composition
WO2024030933A1 (en) 2022-08-02 2024-02-08 Nutrition & Biosciences Usa 1, Llc Novel alginate and cellulose derivative based composition of the liquid anti-reflux formulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744986A (en) * 1986-03-07 1988-05-17 Rorer Pharmaceutical Corporation Process for the preparation of a viscosity-stable antacid composition
WO1996027368A1 (en) * 1995-03-03 1996-09-12 Reckitt & Colman Products Limited Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate
US20050089577A1 (en) * 2002-03-04 2005-04-28 Hideakira Yokoyama Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
US20080317855A1 (en) * 2005-07-28 2008-12-25 Reckitt Benckiser Healtcare (Uk) Limited, Particulate Compositions Comprising Alginate and/or Alginic Acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744986A (en) * 1986-03-07 1988-05-17 Rorer Pharmaceutical Corporation Process for the preparation of a viscosity-stable antacid composition
WO1996027368A1 (en) * 1995-03-03 1996-09-12 Reckitt & Colman Products Limited Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate
US20050089577A1 (en) * 2002-03-04 2005-04-28 Hideakira Yokoyama Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
US20080317855A1 (en) * 2005-07-28 2008-12-25 Reckitt Benckiser Healtcare (Uk) Limited, Particulate Compositions Comprising Alginate and/or Alginic Acid

Also Published As

Publication number Publication date
WO2012128520A2 (ko) 2012-09-27
KR20120108218A (ko) 2012-10-05

Similar Documents

Publication Publication Date Title
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
MX2015009037A (es) Enjuague nasal con miel.
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
WO2012062925A3 (en) Compounds and methods for treating pain
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
DK3045456T3 (da) Bicyklisk substituerede uraciler og anvendelse heraf
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
WO2012128520A3 (ko) 위식도 역류질환 치료용 액상 타입 조성물
PH12014502071A1 (en) Beta-hydroxy-beta-methylbutyric acid for imrpoving glucose tolerance
MX363549B (es) Composiciones farmacéuticas sólidas antidiabéticas.
EA200970816A1 (ru) Новая лекарственная форма
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
WO2009152052A8 (en) Methods of treating alpha adrenergic mediated conditions
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
WO2011093647A3 (en) Genes implicated in osteoarthritis and use thereof
GEP20156373B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
FR2974989B1 (fr) Lit, notamment lit medicalise pour le traitement de patients a domicile
WO2011161295A3 (es) Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760933

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12760933

Country of ref document: EP

Kind code of ref document: A2